Retour sur lavenir.net
   NEXTENSA 46.465 € (-0,18 %)     AEDIFICA 66.350 € (+0,38 %)     VASTNED 27.850 € (-0,71 %)     CIE BOIS SAUVAGE 303.000 € (+1,34 %)     FAGRON 21.700 € (-0,23 %)     IMMOBEL 19.450 € (+0,52 %)     AB INBEV 68.820 € (+0,09 %)     UCB 210.000 € (+0,05 %)     PROXIMUS 6.390 € (+0,16 %)     TINC 10.920 € (+0,37 %)     BEKAERT 37.400 € (+0,27 %)     D'IETEREN GROUP 169.100 € (-0,76 %)     KINEPOLIS GROUP 49.200 € (+0,41 %)     BREDERODE 105.800 € (+0,38 %)     ARGENX SE 853.400 € (-0,63 %)     FLUXYS BELGIUM D 21.600 € (-2,70 %)     SOFINA 254.000 € (-0,55 %)     GIMV 46.250 € (+0,76 %)     KBC 132.100 € (+0,84 %)     AGEAS 75.750 € (+0,33 %)     GBL 74.750 € (-0,20 %)     UMICORE 21.860 € (+1,11 %)     EVS 27.750 € (-0,36 %)     DECEUNINCK 2.455 € (+0,61 %)     BARCO 7.370 € (0,00 %)     MELEXIS 65.050 € (+1,64 %)     SYENSQO 78.400 € (+1,03 %)     COLRUYT 38.080 € (-1,91 %)     VIOHALCO 15.500 € (-0,13 %)     ONTEX GROUP 2.155 € (-0,46 %)     AZELIS GROUP 11.860 € (-0,84 %)     CFE 10.650 € (+1,43 %)     LOTUS BAKERIES 12 000.000 € (-1,15 %)     KBC ANCORA 94.300 € (+0,53 %)     ELIA GROUP 117.500 € (+0,95 %)     TITAN S.A. 49.220 € (-0,04 %)     ACKERMANS V.HAAREN 271.600 € (+0,82 %)     WDP 20.900 € (+0,58 %)     DEME GROUP 180.400 € (+0,45 %)     TUBIZE-FIN 178.400 € (+0,22 %)     MONTEA 64.400 € (+2,55 %)     ATENOR 0.996 € (0,00 %)     CENERGY 22.040 € (+0,09 %)     BPOST 1.224 € (-0,81 %)     HOME INVEST BE. 18.080 € (+0,11 %)     XIOR 25.150 € (+0,60 %)     BIOTALYS 2.085 € (+3,47 %)     OXURION 0.003 € (+16,67 %)     RECTICEL 12.540 € (-0,32 %)     SOLVAY 25.920 € (+0,31 %)     SOLVAC NOM(RETAIL) 82.000 € (0,00 %)     CARE PROPERTY INV. 12.280 € (+0,49 %)     CMB.TECH 16.940 € (-0,24 %)     VGP 72.300 € (+1,83 %)     ABO GROUP 3.860 € (+2,12 %)     QUESTFOR GR-PRICAF 2.921 € (-1,00 %)     NYXOAH 1.368 € (-0,15 %)     RETAIL ESTATES 63.900 € (+0,31 %)     WAREHOUSES ESTATES 37.400 € (+1,08 %)     SHURGARD 22.800 € (0,00 %)  
   ATON 0.014 € (-1,39 %)     BANIJAY GROUP 8.380 € (-0,48 %)     VIRIDIEN 91.750 € (-0,27 %)     CVC CAPITAL 12.960 € (-0,77 %)     TONNER DRONES 0.025 € (-2,69 %)     74SOFTWARE 38.300 € (0,00 %)     FDJ UNITED 21.980 € (-0,77 %)     LEGRAND 134.500 € (+1,17 %)     UBISOFT ENTERTAIN 5.530 € (-0,07 %)     AIR LIQUIDE 166.140 € (-0,06 %)     STELLANTIS NV 4.320 € (-3,72 %)     NEXITY 5.440 € (-0,46 %)     BASSAC 40.300 € (-0,49 %)     2CRSI 27.700 € (+4,14 %)     SOCIETE GENERALE 73.470 € (+0,98 %)     THALES 237.200 € (-1,13 %)     REXEL 36.060 € (+1,52 %)     ASML HOLDING 1 409.600 € (+2,23 %)     TOTALENERGIES 80.890 € (+0,50 %)     SBM OFFSHORE 36.600 € (+1,89 %)     TECHNIP ENERGIES 30.200 € (+0,87 %)     X-FAB 5.965 € (+4,47 %)     HERMES INTL 1 359.000 € (-1,16 %)     PROSUS 35.825 € (-1,70 %)     LVMH 403.250 € (-0,79 %)     AXA 43.580 € (-0,09 %)     RUBIS 35.840 € (+0,67 %)     THEON INTERNAT 31.020 € (-1,02 %)     ADYEN 912.700 € (-2,03 %)     NICOX 0.335 € (+0,90 %)     WOLTERS KLUWER 67.680 € (-1,46 %)     EIFFAGE 106.600 € (+0,85 %)     NEXANS 134.400 € (+0,75 %)     SONAE 2.025 € (-0,25 %)     STMICROELECTRONICS 42.585 € (+1,91 %)     DRONE VOLT 0.346 € (+2,79 %)     ABN AMRO BANK N.V. 42.850 € (+0,37 %)     BE SEMICONDUCTOR 180.050 € (+2,10 %)     TME PHARMA 0.125 € (+24,55 %)     ASM INTERNATIONAL 775.000 € (+3,33 %)     VIVENDI SE 1.539 € (+0,59 %)     CSG 15.622 € (-1,86 %)     ACCOR 45.420 € (+0,69 %)     RANDSTAD NV 36.850 € (-1,34 %)     DASSAULT SYSTEMES 20.630 € (-1,81 %)     AIRBUS 194.920 € (+0,06 %)     SCHNEIDER ELECTRIC 277.450 € (+0,78 %)     DBV TECHNOLOGIES 2.118 € (+2,32 %)     AMG 29.160 € (+0,90 %)     Vusion 115.600 € (+0,87 %)     SAFRAN 323.300 € (+0,31 %)     VALLOUREC 19.620 € (+4,92 %)     EXOR NV 70.600 € (-0,63 %)     ING GROEP N.V. 31.925 € (+0,74 %)     KERING 234.450 € (+0,04 %)     HAFFNER ENERGY 0.597 € (+0,84 %)     J.MARTINS,SGPS 17.580 € (-1,18 %)     GETLINK SE 18.580 € (+0,43 %)     SIF HOLDING 3.415 € (+0,44 %)     SHELL PLC 42.555 € (-0,34 %)  
News Réglementées
17/08/2026 16:05

Mavrix Makes the Case for Trusted Human Evidence in the AI Era at Quirk's New York

EQS-News: Mavrix / Key word(s): Miscellaneous/Miscellaneous
Mavrix Makes the Case for Trusted Human Evidence in the AI Era at Quirk's New York

17.08.2026 / 16:05 CET/CEST
The issuer is solely responsible for the content of this announcement.


NEW YORK, Aug. 17, 2026 /PRNewswire/ -- Mavrix, the global data acquisition and research execution company, used its Platinum Sponsorship of The Quirk's Event New York 2026 to advance a clear view on the changing research landscape: as artificial intelligence makes data generation and analysis faster and more accessible, the ability to reach, verify and engage the right real people is becoming more valuable, not less.

Mavrix Makes the Case for Trusted Human Evidence in the AI Era at Quirk’s New York

Held July 29–30 at the Javits Center, Mavrix participated in two featured sessions, first with Delineate and then with Boston Consulting Group (BCG) and Knit.

In 'Free Data, Worthless Data: What's Actually Left Worth Paying For,' Mavrix and Delineate examined how AI is automating survey creation, coding, summarization, analysis and reporting. The session's central argument was that as routine production becomes easier to automate, value shifts toward evidence that is harder to replicate: proprietary and timely signals, verified human participation, hard-to-reach audiences and judgment about what matters.

"AI gives our industry extraordinary capabilities," said Glen Collins, EVP, Global Commercial Group at Mavrix. "But AI cannot fix speaking to the wrong people. If the human evidence underneath is weak, technology simply allows us to analyze weak evidence faster and with greater confidence. Better human evidence in means better intelligence out."

Mavrix also described verification as a Human Evidence Chain: Reach, Qualify, Verify, Engage and Defend. The objective is not more checks, but evidence that can withstand scrutiny when findings are challenged.

On Day 2 of the Quirk's conference, Mavrix joined BCG and Knit to discuss Qual-at-Scale, examining how AI moderation, video and analysis can enable richer participant conversations at greater speed and scale. For Mavrix, a key implication is that participant eligibility alone is no longer enough. Richer tasks require people who are relevant, articulate, engaged, authentic and ready to contribute.

Across both sessions, Mavrix's message converged around three factors: speed, quality and AI. Speed makes research timely enough to influence a decision. Quality makes the evidence worth acting on. AI helps surface patterns at previously impractical scale.

Mavrix also reinforced a broader principle: the audience should determine the recruitment method, not the other way around. Online, telephone, specialist communities, face-to-face and mixed methods may all be appropriate depending on the audience and market.

For more information, visit www.mavrixdata.com

Media Contact
media@mavrixdata.com 

Mavrix Logo

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/mavrix-makes-the-case-for-trusted-human-evidence-in-the-ai-era-at-quirks-new-york-302852901.html

rt.gif?NewsItemId=EN27414&Transmission_Id=202608171000PR_NEWS_EURO_ND__EN27414&DateId=20260817


17.08.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2384254  17.08.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière